Immunome, Inc. develops targeted cancer therapies through a clinical-stage oncology pipeline that includes varegacestat, an investigational oral gamma secretase inhibitor for desmoid tumors, IM-1021, a ROR1 antibody-drug conjugate, and IM-3050, a FAP-targeted radiotherapy. Company news commonly covers clinical data, regulatory submissions, IND-related progress, oncology conference presentations, and updates on antibody-drug conjugate programs for solid tumors.
Recurring corporate updates also include financial results, business progress reports, investor conference participation, equity compensation actions under the 2024 Inducement Plan, and Nasdaq Listing Rule 5635(c)(4) inducement grants for new employees.
Immunome (IMNM) granted stock options and restricted stock units to ten new employees on October 1, 2026, under its inducement plan.
The awards comprise options to purchase 120,900 common shares at an exercise price of $20.89 per share, equal to that day's closing sales price, and 7,200 restricted stock units (RSUs). The Compensation Committee approved the grants under Nasdaq Listing Rule 5635(c)(4). Options vest over four years: 25% after one year, then the balance monthly over 36 months. RSUs vest 25% annually over four years. Both require continued employee service through the applicable vesting dates.
Immunome (IMNM) has received FDA clearance of its investigational new drug application for IM-1340, an antibody-drug conjugate targeting advanced solid tumors.
The company expects to start a Phase 1 first-in-human study in the fourth quarter of 2026. IM-1340 is its fifth program in clinical development. The therapy combines an antibody targeting a transport receptor with HC74, a payload designed to inhibit the enzyme topoisomerase I. Its target is expressed across tumors including neuroendocrine tumors, lung cancer and colorectal cancer. Preclinical studies demonstrated anti-tumor activity across multiple tumor models.
Immunome (IMNM) granted inducement stock options on September 1, 2026 to four new employees under its 2024 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards consist of non-statutory options to purchase an aggregate of 86,500 shares of common stock, each with an exercise price of $27.07, equal to the closing sales price on the grant date. The options vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the remaining 75% vesting in equal monthly installments over the following 36 months, subject to continued service. The options are governed by the terms of the 2024 Inducement Plan and the applicable stock option agreements.
Immunome (IMNM)/b) will present at H.C. Wainwright’s 28th Annual Global Investment Conference on September 14, 2026, at 11:00 a.m. ET.A live audio webcast will be available through the Investor Relations section of Immunome’s website. A replay of the webcast will be accessible for approximately 30 days after the live presentation.
Immunome (Nasdaq: IMNM) reported second quarter 2026 results and a broad oncology pipeline update. As of June 30, 2026, cash, cash equivalents and marketable securities totaled $520.0 million, which Immunome expects will fund operations into 2028. Q2 2026 collaboration revenue was zero versus $4.0 million a year earlier; research and development expenses were $59.9 million and general and administrative expenses were $18.3 million, resulting in a net loss of $73.1 million (−$0.65 per share).
The U.S. FDA accepted the NDA for varegacestat in desmoid tumors, assigning an April 28, 2027 PDUFA date, following Phase 3 RINGSIDE data showing an 84% reduction in risk of progression or death and a 56% objective response rate. Phase 1 studies of IM-1617 and IM-3050 began dosing in mid‑2026, and IM-1021 continues with objective responses observed in B‑cell lymphoma.
Immunome (Nasdaq: IMNM) reported that its Board’s Compensation Committee granted inducement stock option awards on August 3, 2026 to nine new employees under the 2024 Inducement Plan. The options cover an aggregate 176,500 shares at an exercise price of $23.01 per share, equal to that day’s closing price.
The options vest over four years, with 25% vesting after one year and the remaining shares vesting monthly over the following 36 months, subject to continued service. The awards were approved as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4) and are governed by the plan and related option agreements.
Immunome (Nasdaq: IMNM) reported dosing the first patient in its Phase 1, first-in-human trial of IM-3050, a fibroblast activation protein (FAP)-targeted radioligand therapy using radioactive lutetium-177 in patients with FAP-expressing advanced solid tumors.
The open-label, multicenter study includes dose escalation and expansion phases to assess safety, tolerability, dosimetry, pharmacokinetics, and preliminary anti-tumor activity. Dose escalation will evaluate repeated escalating doses to establish the maximum tolerated or recommended expansion dose, which will then be further assessed for safety and tolerability in the expansion phase.
Immunome (Nasdaq: IMNM) announced FDA acceptance of its New Drug Application for varegacestat, an oral, once-daily gamma secretase inhibitor for adults with desmoid tumors. The FDA set a PDUFA target action date of April 28, 2027.
The NDA is supported by the Phase 3 RINGSIDE trial, which met its primary endpoint with an 84% reduction in risk of disease progression or death vs. placebo (hazard ratio 0.16, p<0.0001). Key secondary endpoints were also met, including an objective response rate of 56% vs. 9% and significant pain reduction. Varegacestat showed a median best tumor volume change of -83% vs. +11% with placebo and was generally well tolerated; 95% of adverse events were grade 1 or 2.
Immunome (Nasdaq: IMNM) granted inducement stock options to seventeen new employees under its 2024 Inducement Plan on July 1, 2026. Awards cover an aggregate 344,000 shares at a per-share exercise price of $21.49, vesting over four years, consistent with Nasdaq Listing Rule 5635(c)(4).
Immunome (Nasdaq: IMNM) dosed the first patient in a Phase 1, first-in-human trial of IM-1617, a potential first-in-class ADC for advanced solid tumors. IM-1617 uses Immunome’s proprietary HC74 TOP1 inhibitor payload. The open-label, multicenter study will assess safety, tolerability, pharmacokinetics and preliminary anti-tumor activity in colorectal, non-small cell lung, breast and other solid tumors. Immunome also plans IND submissions for ADC candidates IM-1340 and IM-1335 in mid- and late 2026, respectively.